Angion Biomedica shares dive after kidney-disease drug trial discontinued

Angion Biomedica Corp. shares dived 30% to $1.20 in after-hours trading Wednesday after the company said it is discontinuing a Phase 2 trial of ANG-3070 in patients with primary proteinuric kidney diseases.